We are pleased to introduce NurExone Biologic‘s talented team members, each star at a time..! This time it’s our very own Dr. Irit Dolgopyat, PhD, R&D scientist at NurExone! Check out Irit’s interview about her role and work environment: 1. What R&D scientist do? Designing experiments that systematically characterize and improve the
Company’s analysis indicates the successful achievement of its proprietary loading technology for producing exosome-based therapies NurExone is providing an updated release to the previously disseminated release from yesterday to replace several sentences and figures that were included in error. Calgary, Alberta–(Newsfile Corp. – December 1, 2022) – NurExone Biologic Inc.
With its technology showing promising results for spinal cord injuries, NurExone Biologic is making significant progress toward becoming a market leader in exosome-based treatment. Read our industry update below. Read More …
The demand for spinal cord injury (SCI) treatment has increased significantly because of the growing incidence of traumatic spinal cord injuries. According to a 2018 report from the United States National Library of Medicine, the prevalence of traumatic spinal cord injuries in low and middle-income countries was 8.72% per 100,000 people,
With its technology showing promising results for spinal cord injuries, NurExone Biologic is making significant progress toward becoming a market leader in exosome-based treatment. Read our industry update below. The demand for spinal cord injury (SCI) treatment has increased significantly because of the growing incidence of traumatic spinal cord injuries.
This time it’s our very own Dr. Irit Dolgopyat, PhD, R&D scientist at NurExone! Check out Irit’s interview about her role and work environment: 1. What R&D scientist do? Designing experiments that systematically characterize and improve the product. This role engages a great deal of strategic planning and creative problem solving.
“Obtaining U.S. FDA approval for our drug platform remains a priority for NurExone and we intend to continue working towards expediting this process by submitting a Pre-IND meeting request,” said Dr. Lior Shaltiel, CEO of NurExone. “In addition to pursuing our regulatory objective, we are advancing other areas of our business, including securing
Last month NurExone Biologic was hosting an investor webinar through Thesis Capital Inc. to discuss its recent business highlights and growth outlook. You can now watch the webinar with caption. Part 1 | Part 2
A biopharmaceutical company based in Israel is moving closer to revolutionizing the treatment of spinal cord injuries for U.S. patients through regenerative medicine. NurExone Biologic Inc., Ltd., which completed a reverse takeover (RTO) in June 2022 (TSXV: NRX) (FSE: J90), is developing a biotech platform called ExoTherapy. The company will
“The only thing in our hands is to make a company public. When it’s public, everything is transparent, people can invest and that will drive innovation” – Lior Shaltiel, PhD Read More….
